

## SECTION 1: Identification of the substance/mixture and of the company/undertaking

- **1.1 Product identifier**
- **Trade name:** *AlphaLISA® Biotinylated Antibody anti-CXCL9 / MIG (500 µL)*
- **Product number:** *AL280BF*
- **1.2 Relevant identified uses of the substance or mixture and uses advised against**  
*No further relevant information available.*
- **Application of the substance / the mixture** *Laboratory chemicals*
- **1.3 Details of the supplier of the safety data sheet**
- **Manufacturer/Supplier:**  
*PerkinElmer Inc  
549 Albany St  
Boston, MA 02118*
- **Further information obtainable from:**  
*US Technical Support  
800-762-4000*
- **1.4 Emergency telephone number:**  
*If inside USA, call CHEMTREC at 1-800-424-9300  
If outside USA, call CHEMTREC at 1-703-527-3887*

## SECTION 2: Hazards identification

- **2.1 Classification of the substance or mixture**
- **2.1.1 Classification according to Regulation (EC) No 1272/2008**  
*The product is not classified, according to the CLP regulation.*

---

- **2.2 Label elements**
- **Labelling according to Regulation (EC) No 1272/2008** *Void*
- **Hazard pictograms** *Void*
- **Signal word** *Void*
- **Hazard statements** *Void*
- **2.3 Other hazards**
- **Results of PBT and vPvB assessment**
- **PBT:** *Not applicable.*
- **vPvB:** *Not applicable.*

## SECTION 3: Composition/information on ingredients

- **3.2 Chemical characterisation: Mixtures**
- **Description:** *Mixture of substances listed below with nonhazardous additions.*
- **Dangerous components:** *Void*
- **Additional information:** *For the wording of the relevant risk phrases refer to section 16.*

## SECTION 4: First aid measures

- **4.1 Description of first aid measures**
- **General information:** *No special measures required.*
- **After inhalation:** *Supply fresh air; consult doctor in case of complaints.*
- **After skin contact:** *If skin irritation continues, consult a doctor.*
- **After eye contact:** *Rinse opened eye for several minutes under running water.*
- **After swallowing:** *If symptoms persist consult doctor.*
- **4.2 Most important symptoms and effects, both acute and delayed** *No further relevant information available.*

(Contd. on page 2)

**Safety data sheet**  
according to 1907/2006/EC, Article 31

Printing date 08.04.2020

Revision: 08.04.2020

**Trade name: AlphaLISA® Biotinylated Antibody anti-CXCL9 / MIG (500 µL)**

(Contd. of page 1)

- **4.3 Indication of any immediate medical attention and special treatment needed**  
No further relevant information available.

### **SECTION 5: Firefighting measures**

- **5.1 Extinguishing media**
- **Suitable extinguishing agents:** Use fire extinguishing methods suitable to surrounding conditions.
- **5.2 Special hazards arising from the substance or mixture** No further relevant information available.
- **5.3 Advice for firefighters**
- **Protective equipment:** Wear self-contained respiratory protective device.

### **SECTION 6: Accidental release measures**

- **6.1 Personal precautions, protective equipment and emergency procedures** Not required.
- **6.2 Environmental precautions:** No special measures required.
- **6.3 Methods and material for containment and cleaning up:**  
Absorb with liquid-binding material (sand, diatomite, acid binders, universal binders, sawdust).
- **6.4 Reference to other sections**  
See Section 7 for information on safe handling.  
See Section 8 for information on personal protection equipment.  
See Section 13 for disposal information.

### **SECTION 7: Handling and storage**

- **7.1 Precautions for safe handling** No special measures required.
- **Information about fire - and explosion protection:** No special measures required.
- **7.2 Conditions for safe storage, including any incompatibilities**
- **Storage:**
- **Requirements to be met by storerooms and containers:** No special requirements.
- **Information about storage in one common storage facility:** Not required.
- **Further information about storage conditions:** None.
- **7.3 Specific end use(s)** No further relevant information available.

### **SECTION 8: Exposure controls/personal protection**

- **Additional information about design of technical facilities:** No further data; see item 7.
- **8.1 Control parameters**
- **Ingredients with limit values that require monitoring at the workplace:**  
The product does not contain any relevant quantities of materials with critical values that have to be monitored at the workplace.
- **8.2 Exposure controls**
- **Personal protective equipment:**
- **General protective and hygienic measures:**  
The usual precautionary measures are to be adhered to when handling chemicals.
- **Respiratory protection:** Not required.
- **Protection of hands:**  
The glove material has to be impermeable and resistant to the product/ the substance/ the preparation.  
Selection of the glove material on consideration of the penetration times, rates of diffusion and the degradation

(Contd. on page 3)

**Safety data sheet**  
according to 1907/2006/EC, Article 31

Printing date 08.04.2020

Revision: 08.04.2020

**Trade name: AlphaLISA® Biotinylated Antibody anti-CXCL9 / MIG (500 µL)**

(Contd. of page 2)

· **Material of gloves**

The selection of the suitable gloves does not only depend on the material, but also on further marks of quality and varies from manufacturer to manufacturer. As the product is a preparation of several substances, the resistance of the glove material can not be calculated in advance and has therefore to be checked prior to the application.

· **Penetration time of glove material**

The exact break through time has to be found out by the manufacturer of the protective gloves and has to be observed.

· **Eye protection:** Goggles recommended during refilling

### SECTION 9: Physical and chemical properties

· **9.1 Information on basic physical and chemical properties**

· **General Information**

· **Appearance:**

· **Form:** Fluid

· **Colour:** According to product specification

· **Odour:** Characteristic

· **Odour threshold:** Not determined.

· **pH-value:** Not determined.

· **Change in condition**

· **Melting point/freezing point:** Undetermined.

· **Initial boiling point and boiling range:** 100 °C

· **Flash point:** Not applicable.

· **Flammability (solid, gas):** Not applicable.

· **Decomposition temperature:** Not determined.

· **Auto-ignition temperature:** Product is not selfigniting.

· **Explosive properties:** Product does not present an explosion hazard.

· **Explosion limits:**

· **Lower:** Not determined.

· **Upper:** Not determined.

· **Vapour pressure:** Not determined.

· **Density:** Not determined.

· **Relative density** Not determined.

· **Vapour density** Not determined.

· **Evaporation rate** Not determined.

· **Solubility in / Miscibility with water:**

Not miscible or difficult to mix.

· **Partition coefficient: n-octanol/water:** Not determined.

· **Viscosity:**

· **Dynamic:** Not determined.

· **Kinematic:** Not determined.

· **Solvent content:**

· **Water:** 90.0 %

(Contd. on page 4)

**Safety data sheet**  
according to 1907/2006/EC, Article 31

Printing date 08.04.2020

Revision: 08.04.2020

**Trade name: AlphaLISA® Biotinylated Antibody anti-CXCL9 / MIG (500 µL)**

(Contd. of page 3)

· **9.2 Other information** No further relevant information available.

### **SECTION 10: Stability and reactivity**

- **10.1 Reactivity** No further relevant information available.
- **10.2 Chemical stability**
- **Thermal decomposition / conditions to be avoided:** No decomposition if used according to specifications.
- **10.3 Possibility of hazardous reactions** No dangerous reactions known.
- **10.4 Conditions to avoid** No further relevant information available.
- **10.5 Incompatible materials:** No further relevant information available.
- **10.6 Hazardous decomposition products:** No dangerous decomposition products known.

### **SECTION 11: Toxicological information**

- **11.1 Information on toxicological effects**
- **Acute toxicity** Based on available data, the classification criteria are not met.

· **LD/LC50 values relevant for classification:**

**26628-22-8 sodium azide**

Oral	LD50	27 mg/kg (rat)
Dermal	LD50	20 mg/kg (rabbit)

- **Primary irritant effect:**
- **Skin corrosion/irritation** Based on available data, the classification criteria are not met.
- **Serious eye damage/irritation** Based on available data, the classification criteria are not met.
- **Respiratory or skin sensitisation** Based on available data, the classification criteria are not met.
- **CMR effects (carcinogenicity, mutagenicity and toxicity for reproduction)**
- **Germ cell mutagenicity** Based on available data, the classification criteria are not met.
- **Carcinogenicity** Based on available data, the classification criteria are not met.
- **Reproductive toxicity** Based on available data, the classification criteria are not met.
- **STOT-single exposure** Based on available data, the classification criteria are not met.
- **STOT-repeated exposure** Based on available data, the classification criteria are not met.
- **Aspiration hazard** Based on available data, the classification criteria are not met.

### **SECTION 12: Ecological information**

- **12.1 Toxicity**
- **Aquatic toxicity:** No further relevant information available.
- **12.2 Persistence and degradability** No further relevant information available.
- **12.3 Bioaccumulative potential** No further relevant information available.
- **12.4 Mobility in soil** No further relevant information available.
- **12.5 Results of PBT and vPvB assessment**
- **PBT:** Not applicable.
- **vPvB:** Not applicable.
- **12.6 Other adverse effects** No further relevant information available.

EU

(Contd. on page 5)

**Safety data sheet**  
according to 1907/2006/EC, Article 31

Printing date 08.04.2020

Revision: 08.04.2020

**Trade name: AlphaLISA® Biotinylated Antibody anti-CXCL9 / MIG (500 µL)**

(Contd. of page 4)

### **SECTION 13: Disposal considerations**

- **13.1 Waste treatment methods**
- **Recommendation**  
Smaller quantities can be disposed of with household waste.  
Must be specially treated adhering to official regulations.
- **Uncleaned packaging:**
- **Recommendation:** Disposal must be made according to official regulations.

### **SECTION 14: Transport information**

· <b>14.1 UN-Number</b> · <b>ADR, ADN, IMDG, IATA</b>	Void
· <b>14.2 UN proper shipping name</b> · <b>ADR, ADN, IMDG, IATA</b>	Void
· <b>14.3 Transport hazard class(es)</b> · <b>ADR, ADN, IMDG, IATA</b> · <b>Class</b>	Void
· <b>14.4 Packing group</b> · <b>ADR, IMDG, IATA</b>	Void
· <b>14.5 Environmental hazards:</b>	Not applicable.
· <b>14.6 Special precautions for user</b>	Not applicable.
· <b>14.7 Transport in bulk according to Annex II of Marpol and the IBC Code</b>	Not applicable.
· <b>UN "Model Regulation":</b>	Void

### **SECTION 15: Regulatory information**

- **15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture**
- **Directive 2012/18/EU**
- **Named dangerous substances - ANNEX I** None of the ingredients is listed.
- **15.2 Chemical safety assessment:** A Chemical Safety Assessment has not been carried out.

### **SECTION 16: Other information**

The information provided in this Safety Data Sheet is based on our present knowledge, and believed to be correct at the date of publication. However, no representation is made concerning its accuracy and completeness. It is intended as guidance only, and is not to be considered a warranty or quality specification. All materials may present unknown hazards, and should be used with caution. Although certain hazards are described, we cannot guarantee that these are the only hazards which exist. PerkinElmer, Inc. shall not be held liable for any damage resulting from handling or from contact with the product.

- **Abbreviations and acronyms:**  
ADR: Accord européen sur le transport des marchandises dangereuses par Route (European Agreement concerning the International Carriage of Dangerous Goods by Road)  
IMDG: International Maritime Code for Dangerous Goods

(Contd. on page 6)

**Safety data sheet**  
according to 1907/2006/EC, Article 31

Printing date 08.04.2020

Revision: 08.04.2020

**Trade name: AlphaLISA® Biotinylated Antibody anti-CXCL9 / MIG (500 µL)**

(Contd. of page 5)

*IATA: International Air Transport Association**GHS: Globally Harmonised System of Classification and Labelling of Chemicals**EINECS: European Inventory of Existing Commercial Chemical Substances**ELINCS: European List of Notified Chemical Substances**CAS: Chemical Abstracts Service (division of the American Chemical Society)**LC50: Lethal concentration, 50 percent**LD50: Lethal dose, 50 percent**PBT: Persistent, Bioaccumulative and Toxic**vPvB: very Persistent and very Bioaccumulative*

-EU-